SAB Bio (SAB Biotherapeutics, Inc.) recently released further data from a Phase I clinical trial of its candidate drug SAB-142 in adult patients diagnosed with autoimmune type 1 diabetes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Synthetix Protocol DAO transfers 428,000 stolen SNX
Is cutting AI spending more beneficial? Bank of America gives a counterintuitive judgment: although “unpopular,” it may extend the economic cycle, and chip stocks could enjoy a longer profit runway.
Bank of America: Chip companies cutting capital expenditures may be “unpopular,” but it could extend the earnings cycle.
How will US stocks move after the midterm elections? Wolfe warns of a "wall of worry" about AI, while Morgan Stanley says the correction is nearing its end.
The "wall of worry" surrounding AI stands in the way, with Nvidia’s earnings report and oil prices becoming key variables.
Yen loses ground to the Dollar despite US-Iran deal hopes
Crypto prices
More
